DGCI gives emergency approval of DRDO-developed anti-Covid oral drug | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 10, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 10, 2025
DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

Coronavirus chronicle

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

The oral drug has been developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. Phase III clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm
Indian Prime Minister Narendra Modi. Photo: NDTV
Indian Prime Minister Narendra Modi. Photo: NDTV

An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories, Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from Covid in the ongoing pandemic.

Pursuing the Hon'ble Prime Minister's call for preparedness against the pandemic, DRDO took the initiative of developing anti-Covid therapeutic application of 2-DG. In April 2020, during the first wave of pandemic INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India's (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in Covid-19 patients in May 2020.

DRDO along with its industry partner Dr Reddy's Laboratories (DRL, Hyderabad) started the clinical trials to test the safety and efficacy of the drug in Covid-19 patients. In Phase-II trials (including dose ranging) conducted during May to October 2020, the drug was found to be safe in Covid-19 patients, and showed significant improvement in their recovery. Phase IIa was conducted in 6 hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients. In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SOC.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Top News / World+Biz

DGCI / Defence Research and Development Organisation (DRDO) / Covid oral drug / oral drug

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • CA orders police, BGB, Ansar to complete election preparation by December
    CA orders police, BGB, Ansar to complete election preparation by December
  • Representational image. Photo: Collected
    Bangladesh-US two-day tariff talks begin in Washington
  •  Chinese investors want better infrastructure in Bangladesh to boost joint ventures
    Chinese investors want better infrastructure in Bangladesh to boost joint ventures

MOST VIEWED

  • File Photo: Rajib Dhar/TBS
    Bangladesh faces economic impact as US introduces 35% tariff on exports
  • None saw it coming: What went wrong in Bangladesh’s tariff negotiation with US 
    None saw it coming: What went wrong in Bangladesh’s tariff negotiation with US 
  • Clashes took place between police and protesters in Sylhet on 2 August. Photo: TBS
    Hasina authorised deadly crackdown on protesters during 2024 July uprising, BBC verifies leaked audio
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    BB governor asks banks to create forced loans for unpaid import LCs
  • Representational image. Photo: TBS
    35% US tariff to be disastrous for Bangladesh's exports, say economists and exporters
  • Trump's 35% tariff zaps Bangladesh's $8.4 billion export lifeline
    Trump's 35% tariff zaps Bangladesh's $8.4 billion export lifeline

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

Features

Women are forced to fish in saline waters every day, risking their health to provide for their families. Photo: TBS

How Mongla’s women are bearing the brunt of rising salinity

3h | Panorama
Dr Mostafa Abid Khan. Sketch: TBS

Actual impact will depend on how US retailers respond: Mostafa Abid Khan

1d | Economy
Thousands gather to form Bangla Blockade in mass show of support. Photo: TBS

Rebranding rebellion: Why ‘Bangla Blockade’ struck a chord

2d | Panorama
The Mitsubishi Xpander is built with families in mind, ready to handle the daily carpool, grocery runs, weekend getaways, and everything in between. PHOTO: Akif Hamid

Now made-in-Bangladesh: 2025 Mitsubishi Xpander

2d | Wheels

More Videos from TBS

Leaked audio: Jinping thought Trump was crazy

Leaked audio: Jinping thought Trump was crazy

32m | TBS World
What can be done to counter the impact of US tariffs?

What can be done to counter the impact of US tariffs?

1h | Podcast
Elections can be held before Ramadan if preparations are complete: Press Secretary

Elections can be held before Ramadan if preparations are complete: Press Secretary

2h | TBS Today
US signals tougher action if Gaza ceasefire talks fail

US signals tougher action if Gaza ceasefire talks fail

1h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net